CBLB and cancer: Using a high throughput screening, Sharp et al. identified and developed a triazole based compound series targeting the E3 ligase activity of Cbl-b, including Nx-1607, which is currently in clinical trials as a cancer immunotherapeutic for the treatment of solid tumor malignancies (clinical trials.gov ID: NCT05107674)23,24.